Science

$Deniz Can Guven: Toripalimab phase I data in refractory CCA$

Photo taken from Deniz Can Guven/X

Jan 28, 2025, 06:20

Deniz Can Guven: Toripalimab phase I data in refractory CCA

Deniz Can Guven, The Editorial Board Member of BMC Cancer and Medical Oncologist at Health Sciences University, shared a recent article by Amit Mahipal et al. on X:

“Toripalimab phase I data in refractory CCA:

The first study with Toripalimab in the US.
Manageable side effects.
Acceptable disease control (40%).
Could additional IO options improve access?

“Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study“

Authors: Amit Mahipal, Milind Javle, Judy Wang, Todd M. Bauer, David L. Bajor, Anthony D. Elias, Anthony Shields, Elizabeth Davis, Sant Chawla, Howard Safran, John D. Powderly, Gina D’Amato, Christian F. Meyer, Xiongwen Tang, Sheng Yao and Patricia Keegan

$Deniz Can Guven: Toripalimab phase I data in refractory CCA 1$

More posts featuring Deniz Can Guven.

Amit Mahipal cancer cholangiocarcinoma Christian F Meyer David L. Bajor Deniz Can Guven disease Judy Wang Milind Javle OncoDaily Oncology Patricia Keegan Sheng Yao Todd M Bauer Toripalimab phase I Xiongwen Tang

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer